Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
Authors:
- 12 December 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 14 (2) , 125-136
Abstract
Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. Combining ICIs, such as atezolizumab, with chemotherapy and/or targeted therapies may help to address this unmet need. Areas covered: Atezolizumab is an anti–programmed death-ligand 1 therapy for several tumor types. We review its clinical efficacy and safety in the treatment of advanced or metastatic NSCLC, with a specific focus on the combination of atezolizumab with bevacizumab, carboplatin, and paclitaxel (ABCP). Data from IMpower150 show that the ABCP regimen provided clinical benefit to patients with non-squamous NSCLC, including those with EGFR mutations. Expert opinion: Combining ICIs with chemotherapy has proven to be superior to chemotherapy alone. However, tumor resistance to ICIs will likely increase as these drugs enter earlier lines of therapy, underscoring a need for effective treatments when immunotherapy fails. Data suggest that the ABCP regimen may circumvent ICI resistance mechanisms. Continued investigation into the regimen’s mechanisms, improved patient profiling/selection, and treatment personalization will drive further development/discoveries.Keywords
This publication has 63 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic ResistanceJournal of Clinical Oncology, 2010
- The functional role of Notch signaling in human gliomasNeuro-Oncology, 2009
- Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implicationsBMC Cancer, 2009
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyondLaboratory Investigation, 2008
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma linesInternational Journal of Cancer, 2002
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002